ArticleThe World Allergy Organization journal2026
A four-year journey towards clinical remission and background therapies optimization with benralizumab: A retrospective analysis.
Article in The World Allergy Organization journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Clinical remission is increasingly recognized as a primary treatment goal in severe asthma, particularly severe eosinophilic asthma (SEA), where comorbidities such as chronic rhinosinusitis with nasal polyps (CRSwNP) contribute to persistent inflammation and treatment burden. Benralizumab, an anti-IL-5Rα monoclonal antibody, has shown efficacy in achieving sustained control in SEA, but long-term real-world data beyond 36 months remain limited. Objective: To evaluate the long-term (48-month) effectiveness of benralizumab in SEA patients, focusing on clinical remission, airway function, and reduction of background therapy, including oral corticosteroids (OCS) and inhaled corticosteroids (ICS). Methods: In this retrospective, multicenter study across 9 Italian centers, 128 adult SEA patients (mean age 57.1 years, 57% female; 59.4% with CRSwNP) were treated with subcutaneous benralizumab for up to 48 months. Clinical remission was assessed using SANI criteria: partial (pCR, meeting ≥2 of 3 criteria without OCS) and complete (cCR, all criteria fulfilled without OCS). Outcomes included annualized exacerbation rate (AER), pulmonary function (FEV Results: Benralizumab induced rapid and sustained improvements. AER decreased from 3.62 to 0.33 at 48 months; blood eosinophils were nearly undetectable throughout. FEV Conclusions: Long-term benralizumab treatment in SEA patients leads to rapid, sustained clinical remission, improved large and small airway function, and significant reduction of background therapy, including OCS and ICS. These results support the role of benralizumab as a disease-modifying therapy and highlight the feasibility of remission-based management in real-world practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.